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Introduction. Use of Pavlik harness for the treatment of DDH can be complicated for parents. Any misuse or failure in the
adjustments may lead to significant complications. An abduction brace was introduced in our institution, as it was thought to
be easier to use. Aim. We assess the results for the treatment of DDH using our abduction brace in children of 0–6 months old and
compare these results with data on treatments using the Pavlik harness.Method. Retrospective analysis of patients with DDH from
0 to 6months old at diagnosis, performed from 2004 to 2009. Outcomes were rates of reduction of the hip and avascular necrosis of
the femoral head (AVN). Follow-up was at one year and up to 4 years old. Results. Hip reduction was successful in 28 of 33 patients
(85%), with no AVN. Conclusion. Our results in terms of hip reduction rate and AVN rate are similar to those found in literature
assessing Pavlik harness use, with a simpler and comfortable treatment procedure.
1. Introduction
Developmental dysplasia of the hip (DDH) is defined by
acetabular dysplasia, which can lead to hip dislocation. For
children from 0 to 6 months old with a confirmed DDH,
the position for treatment is bending and abducion of the
hips, using a restraining device such as Pavlik’s harness [1, 2].
This harness was developed to improve hip reduction rates
and reduce the incidence of femoral head avascular necrosis
(AVN). Unlike other methods, such as the von Rose braces,
the Becker, and Mittelmeier abduction pillow or other rigid
abduction braces, Pavlik’s harness is a dynamic positioning
device that avoids complete immobilization of the joint [3–7].
The absence of external constrains allows gradual and gentle
reduction and stabilization of the hip. The success of Pavlik’s
method is now well established [8–12].
However, AVNhas not disappeared and remains a serious
complication. Furthermore, failure of hip reduction can
still occur with the harness [13–15]. Other complications
as femoral neuropathy, brachial plexus neuropathy, knee
subluxation, or skin lesions have also been described [5, 7, 16].
According toMubarak et al. [16] thesemostly occur following
inappropriate medical indication or misuse of the harness. A
lack of treatment compliance by parents can be a challenging
cause of failure. The use of Pavlik’s harness requires regular
medical check-ups, frequent technical adjustments, and con-
tinuous parental monitoring. It puts pressure on parents in
terms of both costs and compliance [16, 17].
In 2003,Hedequist et al. [18] reported encouraging results
with the use of an abduction bracewhen stabilizationwith the
Pavlik harness failed.They also valued the ease of application
for the parents and therapist. Following this publication, we
decided to replace the use of the Pavlik harness with a custom
made abduction brace for the treatment of DDH in children
up to 6 months old. The brace would be easier to use than
Pavlik’s harness but would preserve the therapeutic advan-
tages and characteristics, which contribute to its success. The
objectives of this study were to assess the brace’s efficacy and
safety, in terms of hip reduction rate and AVN rate, and to
compare our results with those of Pavlik’s harness.
2. Materials and Methods
We performed a retrospective review of the medical records
of all the children from 0 to 6 months old at diagnosis with
clinically and imaging confirmed DDH. They were treated
in 2 hospitals close to our institution from 2004 to 2009.
ChildrenwithDDHsecondary to neurological,myopathic, or
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Table 1: Clinical findings: algorithm.
(a)
Clinical findings and risk factors (RF) Code
(A) Dislocated (1) Nonreducible A1
(2) Reducible A2
(B)
Nondislocated
(1) Unstable
(1.1) Unstable
after 1-2 weeks B11
(1.2) Stable after
1-2 weeks B12
(2) Stable (2.1) Positive RF B21
(2.2) Negative
RF B22
(b)
Code Management
A1 US + traction + cast
A2 US + abduction brace
B11 US + abduction brace
B12 US at 4–6 weeks, routine physical examination
B21 US at 4–6 weeks, routine physical examination
B22 Routine physical examination
connective tissue diseases were excluded; two other patients
were excluded because of data loss. In one patient with
Graf 4 dysplasia, we decided to immediately initiate a closed
reduction with cast, and so he was also excluded from
the study. All the patients had been treated by the same
surgeon, and ultrasound (US) follow-up evaluations had been
performed by trained radiologists. No other methods were
used as first-line in this age group.
We looked at 40 dysplastic hips affecting 33 patients.
Seven dysplastic hips were bilateral. We reported on 10 Graf
type 2a hips, 12 type 2b hips, 8 type 2c hips, 7 type 3 hips,
and 1 type 4 hip. One patient had a normal hip—Graf US type
1—despite a clearly pathological status. Another 6-month-old
infant did not receive a US examination but a pelvis X-ray
instead and thus was not classified using the Graf method.
All 33 patients had a follow-up at 1 year old and 28 patients at
3-4 years old (85%).
Systematic clinical assessment of the hips was performed
at birth. A negative clinical examination at birth, without risk
factors, leads to the routine clinical follow-up at 4–6 weeks
old. In case of a positive risk factor (positive family history,
breech delivery, oligoamnios, and twins), US evaluation was
performed at 4–6 weeks old. In cases of positive clinical
findings for hip luxation at birth, a US evaluation of the
hip joint was performed at 1-2 weeks old. At this time, fully
dislocated hips were splinted. Immature hips were controlled
with US follow-up 1-2 and 4–6 weeks later, as normalization
within the first weeks of life is frequent [19, 20]. The brace
treatment was only initiated in confirmed DDH after this
time. Inconclusive examinations were reassessed every 2
weeks until a final diagnosis was made (Table 1).
Our decisions to treat DDHwith an abduction brace were
based on both clinical evaluation and results of the imaging
Figure 1: Brace, view from front.
studies (Table 2). The US diagnosis of DDH was based on
the Graf hip classification, which uses 𝛼 and 𝛽 angles, as well
as the acetabular coverage, which was estimated at higher or
lower than 50%.
The custom made brace used in Lausanne was conceived
following Hedequist et al.’s publication. Initial prototypes
were made based on Hedequist’s design, but through a
collaborative process between physicians, occupational ther-
apists, and parents, we arrived at our current improved
device (Figures 1, 2, 3, and 4). The brace design comes
as close as possible to a dynamic positioning orthosis. It
thus differs from earlier abduction splints, which completely
immobilized the hips and, therefore, caused a high rate of
AVN [7].
Plastazote foam, a quite flexible material allowing some
degree of mobility, is molded on the infant’s body from
the level of the armpits to the low pubis and enables splint
adjustment to the size of each individual newborn. Thighs
are embraced, but the bending area is kept free for limb
movements; knees are free of constraint and are able to move.
The internal hull is reinforced by a second, external plastic
layer, covering the back and thigh areas and is made of
aquaplast, a semirigid foam.This can be tightened should the
newborn be too active. In order to reinforce hip’s bending
and abduction, more rigid material can be added around
the buttocks area. Flexion and abduction, between 90∘ and
100∘, are adjustable through a rigid strap at the front of the
body and through an elastic strap at the back. The back strap
usually allows maximal abduction amplitude. This elastic
strap and the flexibility of plastazote prevent a rigid hip
immobilization which might alter the vascularization of the
femoral head.
At early stages of treatment, the physician’s recommenda-
tion was usually “let’s try it and see,” without any undue hurry
for the perfect position. This was followed by progressive
moves towards a perfect fit, through heating and molding
the brace. In this way, we ensured that hips were gradually
reduced without excessive hardship. During this period,
the splints were removed daily, at bath and feeding times
only, which still corresponded to 23 h wearing time per
day. Follow-up consisted of a monthly medical examination
and US. From 4 months old, US was replaced by pelvic
radiography, and we assessed hip evolution by calculating the
acetabular Hilgenreiner angle.
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Table 2: US results and medical management: algorithm (adapted fromMahan et al. [21]).
Age Alpha angle Graf type Medical management
<3 months old
>60∘ I Clinical follow-up
50–60∘ IIa Repeating US at4–6 weeks old
Improvement US follow-up
Unchanged or worse Treatment
<50∘ III, IV Treatment
>3 months old >60
∘ I Clinical follow-UP
<60∘ IIb, IIc, III, IV Treatment
Figure 2: Brace on the child, view from front.
Figure 3: Brace, view from behind.
Medical examinations required a brief removal of the
brace on a regular basis. If a positive response and stabi-
lization occurred, we indicated a part-time treatment and
night-time brace wear only. When the hip’s evolution was
not satisfactory, we proceeded towards arthrography, closed
reduction of the hip, and cast. After this, the splints wereworn
part-time, at night, for 2 months. Another X-ray was taken
at 1-year old to document any residual dysplasia or signs of
AVN. We carried out further tests, clinical and radiological,
at 3-4-years old. The criteria for success were satisfactory hip
reduction and an absence of evidence of AVN at 1- and 4-
year old. Finally, we compared our results with those in the
literature about Pavlik’s harness.
3. Results
The abduction brace allowed reduction in 28 out of 33
patients (85%) (Tables 3 and 4). In 5 cases, this method was
Figure 4: Brace on the child, view from behind.
insufficient; thus a closed reduction and cast became the next
therapeutic option. All Graf types IIa, IIb, and IIc unilateral
dysplasias were successfully reduced by our abduction brace
and in 4 out of 6 unilateral type III (66%). The patient with
Graf type IV hip was not successfully reduced. Reduction was
achieved in 4 out of 7 of bilateral dysplasia (57%).
At 1-year old, 9 patients (27%) showed persistent dys-
plasia above standard intervals for their age, with higher
Hilgenreiner angle, a slightly eccentric position of the femoral
head, or rupture of the cervicoobturator line. Out of the
28 patients with a follow-up at 3-4-year old, 5 patients
among the 9 patients with persistent dysplasia at 1-year old
had hip normalization and 4 (15%) still showed residual
dysplasia. Regarding AVN, none has been detected and no
other complication due to the brace occurred.
It should be noted that since 2007, 23 out of a total of 24
patients (96%) were successfully treated with the abduction
splint only.The only failure occurred in bilateral types IIc and
IIb dysplasia. Out of these 24 patients, 5 residual dysplasias
remained at the age of 1 year (21%). Out of the 19 patients
with follow-up at 3-4-year old, 3 of the 5 patients with residual
dysplasias at 1-year old had hip normalization and 2 patients
had residual dysplasia (11%).
Regarding unilateral dysplasias (Table 5), the mean age
of brace introduction was 3.1 months (range, 3 weeks old to
6 months old). The wearing time was full-time (23 h/day)
during a mean 3.6-month period (range, 2 months old
to 5 months old), except for the patients undergoing a
secondary reduction. The brace was worn for a total mean
period (first full-time, then part-time at night) of 5.3 months
(range, 3 months to 8 months). Regarding bilateral dysplasias
(Table 6), the mean age of brace introduction was 1.5 months
(range, 1 week old to 3 months old). This treatment had to
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Table 3: Values of unilateral dysplasia.
ID Graf Side
Residual
dysplasia at
1-year old
Residual
dysplasia at
4 years old
Failed reduction AVN Comments
1 2b G 0 0 0 0
2 2b G 0 0 0 0
3 3b G 0 0 1 0 Failure + cast
4 3 D 1 1 1 0 Failure + cast
5 3 G 1 0 0 0
6 1 G 0 0 0 0 Normal image at birthbut pathological clinic
7 2a G 0 0 0 0
8 2b G 0 0 0 0
9 3 G 0 0∗(2) 0 0
10 2b G 0 0 0 0
11 2b G 0 0 0 0
12 2a G 0 0 0 0
13 3 D 0 0 0 0
14 D 1 0 0 0
15 2a G 0 0 0 0
16 2b D 0 0 0 0
17 3 G 0 0∗(3) 0 0
18 2b G 0 0 0 0
19 2a G 0 — 0 0∗(1)
20 2c G 0 0 0 0
21 2b D 1 1 0 0
22 2c D 1 0 0 0
23 2b G 0 — 0 0∗(1)
24 2b G 0 — 0 0∗(1)
25 3 D 0 0 0 0
26 2c G 1 0 0 0
∗(): age at last control.
Table 4: Values of bilateral dysplasia.
ID Graf Residual dysplasia at 1 Residual dysplasia at 4 Failed reduction AVN
D1 D2 D1 D2 D1 D2
1 2b 2b 1 0 1 0 0 0
2 2c 2a 1 0 0∗(3) 0∗(3) 1 0
3 4 2c 0 0 0 0 1 0
4 2c 2a 0 0 0 0 0 0
5 2a 2a 0 0 0 0 0 0
6 2c 2a 1 0 1 0 1 0
7 2c 2a 0 0 — — 0 0∗(1)
∗(): age at last control.
be interrupted and replaced in 3 out of 7 patients, after an
average period of 3 months (range, 1 month to 5 months).
Patients whose hips were reduced using the brace wore them
full-time (23 h/day) over an average period of 6.3 months
(range, 5 months to 8 months). Overall (first full-time and
then part-time), the brace was worn for an average period of
8 months (range, 6 months to 10 months).
4. Discussion
Pavlik’s harness is currently the favored device used to treat
DDH. In literature, reduction rates obtained with this device
range from 80% to 100% [9, 20, 22, 23]. The severity of
DDH can affect the treatment success ratio. Indeed, in severe
luxation, Pavlik’s harness is often ineffective. Reduction
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Table 5: Brace duration, unilateral dysplasia.
ID
Brace,
introduc-
tion age
(months)
Brace
23 h/day
(months)
Total brace
duration
(months)
Secondary
treatment
1 6 3 3
2 3 4 5.5
3 1 1 — Traction,cast
4 4 3 3 Traction,cast
5 1.25 5 7
6 6 3 6
7 2.5 4 6
8 3 2 5
9 1 5 7
10 3 4.5 6.5
11 4 5 6
12 0.75 4.5 7
13 2.5 3 4
14 6 4 6
15 2.5 3 4
16 3.5 3 6
17 5 4 5
18 3 5 8
19 2 3 5
20 1.5 2.5 5.5
21 4 2 3
22 2 4.5 6
23 6 4 6
24 3.5 2.5 5.5
25 1.5 4 6
26 1 5 6
rates with the harness for type 4 dysplasias are as low as
0% for some authors [24, 25], but better results are also
obtained with 50% [26] and 62% [2] of successful reduction
rates. The second important outcome is the AVN rate after
treatment. In literature, commonly reported AVN ratios are
between 0% and 8% [10, 23, 24, 27].
Our Lausanne-developed abduction brace reached simi-
lar therapeutic results to those currently found in the litera-
ture on Pavlik’s harness. In fact, our splint raised reduction
rates to 85% of the cases from 2004 to 2009 and up to 96%
of the reported cases from 2007 to 2009. The increase in
successful outcomes over the last 3 years may be attributable
to improvements in the achievement of the custom made
brace over time, on one hand, and to more numerous low-
range and midrange dysplastic hips encountered, on the
other. The ratio of residual dysplasia at 1-year old was 23.5%
and 15% at 3-4-year old. The other key outcome was a 0%
ratio of AVN. We had no reports of other complications like
femoral nerve issues or skin lesions.
Table 6: Brace duration, bilateral dysplasia.
ID
Brace,
introduc-
tion age
(mo)
Brace
23 h/day (mo)
Total brace
duration
(mo)
Secondary
treatment
1 3 7 9 —
2 0.25 5 Traction,cast
3 1 1 Traction,cast
4 1.5 8 10 —
5 1.5 5 7 —
6 2 3 Traction,cast
7 1 5 6 —
The brace is effective for low-range and midrange Graf
types IIa, b, and c, with a 100% success ratio for unilateral
dysplasia.With type III dysplasia, however, this ratio dropped
to 71.4% (5/7). We were unable to reduce the Graf type
IV case. These results were similar to those obtained with
Pavlik’s harness in some of the literature [24–26] but were less
convincing for severe dysplasia than in Peled et al. study [2].
Bilateral dysplasias produced also a lower reduction rate of
57.1% (4 out of 7); they were often severe and hard to reduce
using only a brace. It should be noted that the failure of brace
treatment in no way affected any secondary treatment by
traction and closed reduction.
The brace was developed to make treatment of DDH
easier to manage for physicians and for parents and children
in day-to-day life. Being made of light, flexible material, its
daily use is very easy for parents. Moreover, our brace allows
the infant to sit. Reshaping the brace during the treatment
is very easily done by slightly heating and molding the
thermoplastic material into the desired position. So with a
splint lifespan of about 3 months, only two different braces
are usually required for the duration of the treatment. One
key element is that the design avoids any maladjustment for
the user, unlike Pavlik’s harness, so that we can manipulate
the brace without any risk of accidents and associated serious
consequences. In our country, the Pavlik harness is charged
400 Euros and the splint 600 Euros. However, while the
harness requires a medical follow-up almost weekly, or
every 2 weeks, the splint allows a follow-up every 3 weeks,
alternately by the occupational therapist and the orthopedic
surgeon.
Given the limited number of patients, we have not
been able to build up significant statistics and figures and,
therefore, to draw firm conclusions. One limitation to the
use of the brace is the presence of well-trained occupational
therapists to make the brace, which cannot be used in every
clinic set-up, or a pediatric orthopedic office. However, in
the light of our results, and given the ease of management
compared to Pavlik’s harness, we are continuing to use our
abduction brace for the treatment of DDH in infants between
0 and 6 months old.
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